Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Celiac Disease Treatment Market to Grow More than Tenfold to $551 Million by 2023Reportstack has annouced a market report on Opportunity Analyzer: Celiac Disease - Opportunity Analysis and Forecast to 2018
By: Reportstack Complete report is available at http://www.reportstack.com/ The company’s latest report on Celiac Disease - Opportunity Analysis and Forecast to 2018 states that the US will continue to account for almost all of the celiac disease therapeutics space, which also includes the five European countries (5EU) of France, Germany, Spain, Italy and the UK. The US share will slip slightly from 99% in 2013 to just under 98% by the end of the forecast period. Abhilok Garg, Ph.D., GlobalData’s Analyst covering Immunology, says that the market will be driven primarily by the potential introduction of two novel pipeline drugs, Alba/Teva’s larazotide acetate and Alvine/AbbVie’ Garg comments: “Larazotide acetate is forecast to launch in the US in Q1 2018, with the key competitive advantage of targeting the majority of the disease population, compared with the 4–7% of refractory patients, who are currently treated with generics including steroids and immunosuppressants. “In Q1 2019, larazotide acetate is expected to launch in the 5EU, while latiglutenase may potentially launch in the US. These pipeline drugs are forecast to increase sales in the six major markets (6MM) from $49.6 million in 2013 to $289.9 million by the end of 2019.” Garg adds that Q1 2020 may see the launch of latiglutenase in the 5EU, thereby boosting the 6MM sales further to $343.3 million, with a steady incline up to $551.1 million by 2023. Despite the anticipated impact of these novel drugs, there are a number of barriers to growth in the celiac disease treatment market, such as limited physician and patient awareness of the condition and a lack of confidence in pipeline drugs compared with a GFD. Garg continues: “Improved physician education concerning GFDs and developments in the gluten-free food market may refine the standard of care and this, in turn, may deter physicians from prescribing adjunctive treatments.” Companies mentioned in this report are AbbVie, ActoGeniX, Alba, Alvine, Avalon, Avaxia, Calypso, Dr Falk, GSK, ImmusanT, Provid, Shire, Sitari, Teva and Zedira. More details about this report can be found at Opportunity Analyzer: Celiac Disease - Opportunity Analysis and Forecast to 2018 (http://www.reportstack.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|